Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pretreatment 18F-FDG Uptake Heterogeneity Predicts Response to Pyrotinib in Patients With Metastatic HER2-positive Breast Cancer

NCT04756921 is registered in ClinicalTrials.gov with Biyun Wang, MD as lead sponsor.

NCT NCT04756921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04756921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pretreatment 18F-FDG Uptake Heterogeneity Predicts Response to Pyrotinib in Patients With Metastatic HER2-positive Breast Cancer
Lead sponsor
Biyun Wang, MD
Phase
Observational
Overall status
Completed
Start date
September 1, 2018
Completion date
July 24, 2020
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer